Literature DB >> 27076198

Soft tissue myxofibrosarcoma: A clinico-pathological analysis of a series of 75 patients with emphasis on the epithelioid variant.

Guido Scoccianti1, Valentina Ranucci2, Filippo Frenos1, Daniela Greto3, Giovanni Beltrami1, Rodolfo Capanna1, Alessandro Franchi4.   

Abstract

BACKGROUND AND OBJECTIVES: The clinical course of soft tissue myxofibrosarcoma is characterized by a high incidence of recurrences and there is no agreement on how to identify patients at major risk. An epithelioid histological variant has been described, with a possible worse prognosis. We reviewed our series to identify prognostic factors and assess clinical significance of the epithelioid variant.
METHODS: We examined the clinico-pathological features of a series of 75 patients affected by soft tissue myxofibrosarcoma at a mean follow-up of 63 months (range 17-132).
RESULTS: Disease specific survival and local recurrence free survival were, respectively, 84.8% and 76.8% at 5 years. Seven patients (8.6%) presented with the epithelioid variant with a survival of 62.5%. High grade and epithelioid morphology were negative prognostic factors for patient survival, high grade, and inadequate surgical margins for local recurrence. Radiotherapy had a local protective effect in high grade tumors.
CONCLUSIONS: Our experience confirms the difficulties in obtaining wide margins in myxofibrosarcoma and the high rate of recurrence. Local recurrences did not significantly affect survival and a limb-sparing approach can be chosen also in recurrences. Patients affected by the epithelioid variant showed a worse prognosis. Chemotherapy should be considered as adjuvant treatment in this subtype. J. Surg. Oncol. 2016;114:50-55.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  epithelioid variant; histopathology; myxofibrosarcoma; prognosis; soft tissue tumors

Mesh:

Substances:

Year:  2016        PMID: 27076198     DOI: 10.1002/jso.24250

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Low-Grade Myxofibrosarcoma of the Rectus Abdominus Muscle Infiltrating into Abdominal Cavity: A Case Report.

Authors:  Tadashi Nomura; Shunsuke Sakakibara; Aya Moriwaki; Teruya Kawamoto; Satoshi Suzuki; Takeshi Ishimura; Kazunobu Hashikawa; Hiroto Terashi
Journal:  Eplasty       Date:  2017-02-21

2.  PROGNOSTIC FACTORS IN PATIENTS WITH APPENDICULAR MYXOFIBROSARCOMA.

Authors:  Juan Pablo Zumárraga; Felipe Augusto Ribeiro Batista; André Mathias Baptista; Marcelo Tadeu Caiero; Luis Pablo de la Rosa Martino; Olavo Pires de Camargo
Journal:  Acta Ortop Bras       Date:  2018       Impact factor: 0.513

3.  Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcoma.

Authors:  Jan Marie de Gooyer; Yvonne M H Versleijen-Jonkers; Melissa H S Hillebrandt-Roeffen; Cathelijne Frielink; Ingrid M E Desar; Johannes H W de Wilt; Uta Flucke; Mark Rijpkema
Journal:  Sci Rep       Date:  2020-02-19       Impact factor: 4.379

4.  OSmfs: An Online Interactive Tool to Evaluate Prognostic Markers for Myxofibrosarcoma.

Authors:  Huimin Li; Longxiang Xie; Qiang Wang; Yifang Dang; Xiaoxiao Sun; Lu Zhang; Yali Han; Zhongyi Yan; Huan Dong; Hong Zheng; Yongqiang Li; Wan Zhu; Xiangqian Guo
Journal:  Genes (Basel)       Date:  2020-12-19       Impact factor: 4.096

5.  Analysis of prognostic factors in 171 patients with myxofibrosarcoma of the trunk and extremities: a cohort study.

Authors:  Huanmei Liu; Xinxin Zhang; Shuguang Zhang; Shengji Yu
Journal:  Ann Transl Med       Date:  2021-08

Review 6.  Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives.

Authors:  Silvia Vanni; Alessandro De Vita; Lorena Gurrieri; Valentina Fausti; Giacomo Miserocchi; Chiara Spadazzi; Chiara Liverani; Claudia Cocchi; Chiara Calabrese; Alberto Bongiovanni; Nada Riva; Laura Mercatali; Federica Pieri; Roberto Casadei; Enrico Lucarelli; Toni Ibrahim
Journal:  Ther Adv Med Oncol       Date:  2022-06-28       Impact factor: 5.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.